Donitriptan hydrochloride

Discontinued Product

Donitriptan hydrochloride (Cat. No. 3665) has been withdrawn from sale for commercial reasons.
Cat.No. 3665 - Donitriptan hydrochloride | C23H25N5O2.HCl | CAS No. 170911-68-9
Description: 5-HT1B/1D agonist
Chemical Name: 1-[[[3-(2-Aminoethyl)-1H-indol-5-yl]oxy]acetyl]-4-(4-cyanophenyl)-piperazine hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Brain penetrant 5-HT1B/1D agonist (pKi values are 9.3 and 9.4 for 5-HT1D and 5-HT1B respectively). Inhibits capsaicin-induced external carotid vasodilation and produces selective carotid vasoconstriction in various animal species. Displays antimigraine activity.

Technical Data

M. Wt 439.94
Formula C23H25N5O2.HCl
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 170911-68-9
PubChem ID 197705
InChI Key ZXENQGQAPOYDOJ-UHFFFAOYSA-N
Smiles NCCC2=CNC1=CC=C(OCC(N3CCN(C4=CC=C(C#N)C=C4)CC3)=O)C=C12.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References

References are publications that support the biological activity of the product.

Letienne et al (2003) Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: further insights into its mechanism of action relevant to headache relief. J.Pharmacol.Exp.Ther. 305 749 PMID: 12606602

Letienne et al (2005) Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: an overlooked mechanism of antimigraine action? J.Pharmacol.Exp.Ther. 315 849 PMID: 16027226

Munoz-Islas et al (2006) Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilation via 5-HT1B rather than 5-HT1D receptors. Br.J.Pharmacol. 149 82 PMID: 16880765

View Related Products by Target

View Related Products by Product Action

View all 5-HT1B Receptor Agonists

Keywords: Donitriptan hydrochloride, Donitriptan hydrochloride supplier, serotonin, 5-HT1B, 5-HT1D, 5-HT1B/1D, receptors, agonists, Receptors, 3665, Tocris Bioscience

Citations for Donitriptan hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Donitriptan hydrochloride.

Reviews for Donitriptan hydrochloride

There are currently no reviews for this product. Be the first to review Donitriptan hydrochloride and earn rewards!

Have you used Donitriptan hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.